• This topic has 1 voice and 0 replies.
Viewing 0 reply threads
  • Author
    • #11854

      Bellerophon‘s positive top-line results from its Phase 2 trial testing INOpulse as a potential therapy for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) will be presented at an upcoming conference, the company announced. Results of the trial, which were initially announced in September 2017, showed that INOpulse, a portable device that delivers a vasodilator gas called nitric oxide, or iNO, improved blood flow and increased patients’ exercise capacity.

      Patients can use the device daily, either at home or elsewhere. Findings from the trial will be presented at he American Thoracic Society 114th International Conference on May 21 in San Diego. Click here to read more: #ATS2018 — Bellerophon Presenting Top-line Results Showing INOpulse’s Benefits in PH-COPD Patients

      Are you familiar with INOpulse therapy? What are your thoughts on this news?

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account